Iron Bioavailability of High Surface Area Ferric Phosphate (HiFe)
Iron Bioavailability of High Surface Area Ferric Phosphate in Thai Women
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Nakhon Pathom
-
Salaya, Nakhon Pathom, Thailand, 73170
- Mahidol university
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Women of reproductive age (18 to 49 years) in Thailand
- BMI < 23 kg/m2
- Body weight < 65 kg
- Mildly anaemic to normocythemic (Hb 80-110 g/L)
- Ferritin < 25 µg/L
- Not pregnant (confirmed by pregnancy test stripe) or lactating
- No inflammation (CRP < 5 mg/L)
- Having provided written informed consent
Exclusion Criteria:
- Haemoglobinopathies (except heterozygosity for haemoglobin E and alpha-thalassemia 1)
- Coeliac disease or other chronic diseases of malabsorption that could influence iron absorption or metabolism
- Blood donation or significant blood loss due to surgery or accident < 4 months before start of the study
- Consumption of vitamin or mineral supplements 2 weeks before start of the study
- Regular use of medication (except oral contraceptives), that influences iron absorption
- Chronic inflammatory disease
- Smoking
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: Single
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Active Comparator: FeSO4 fortified rice test meal
|
Rice test meal extrinsically labeled with 2 mg ferrous sulfate (58FeSO4)
|
|
Experimental: FePO4 fortified rice test meal
|
Rice test meal extrinsically labeled with 2 mg ferric phosphate (58FePO4)
|
|
Experimental: HiFePO4 1 fortified rice test meal
|
Rice test meal extrinsically labeled with 2 mg high surface ferric phosphate 1 (57FePO4)
|
|
Experimental: HiFePO4 2 fortified rice test meal
|
Rice test meal extrinsically labeled with 2 mg high surface ferric phosphate 2 (57FePO4)
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Fractional iron absorption
Time Frame: Measured 14 days after consumption of the 4 different types of iron vehicles (Days 16 and 31)
|
Iron absorption will be determined by measurement of the isotopic ratio change from the 4 different types of iron vehicles (FeSO4 fortified rice test meal, FePO4 fortified rice test meal, HiFePO4 1 fortified rice test meal, HiFePO4 2 fortified rice test meal).
|
Measured 14 days after consumption of the 4 different types of iron vehicles (Days 16 and 31)
|
Collaborators and Investigators
Sponsor
Sponsor
Collaborators
Collaborators
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- HiFe
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.